What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single Arm :It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors”In the company’s words, NCT05277168 on ClinicalTrials.gov
- Tested for
- Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Advanced Solid Tumors and 1 more
- Main trialPhase 3
- “The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients”In the company’s words, NCT06649292 on ClinicalTrials.gov
Other drugs for Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up3
- 20 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 20 Sep 2027 | SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | |
| Phase 2Recruiting | Aug 2026 | A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | |
| Phase 2Recruiting | Dec 2027 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | |
| Phase 2Recruiting | Dec 2030 | A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer | |
| Phase 1/2Recruiting | May 2026 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | |
| Phase 1Active, not recruiting | 1 Dec 2025 | A Study of SHR-A1904 in Patients With Advanced Solid Cancer | |
| Phase 1Unknown | 30 Jun 2023 | A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026